The combinatorial inhibition of CDK1 and BRD4 has the potential to overcome the low specificity of CDK1 inhibitor as well as cancer resistance to BETi, allowing more effective killing of BRD4-driven cancer cells. The gene discussed is CDK1; the disease is cancer.